Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 7/20 | 0.51 |
| ▸ | EGFR | P00533 | 7/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.51 |
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620147 | 0.77 | TYMS (0.61) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL17500020 | 0.75 | EGFR (0.59) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL12391891 | 0.75 | EGFR (0.63) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL28590262 | 0.69 | IMPDH2 (0.47) | GAANPC1RAB9AALDH1A1HPGD | |
| SCHEMBL1923985 | 0.68 | EGFR (0.63) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL29377583 | 0.68 | TYMS (1.00) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL17528544 | 0.68 | EGFR (0.60) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL1997367 | 0.68 | TYMS (1.00) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL1994777 | 0.68 | TYMS (1.00) | TYMSEGFRPDGFRBKDRFLT3 | |
| SCHEMBL17528545 | 0.68 | TYMS (0.57) | TYMSEGFRPDGFRBKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2019-07-11 | — | — | US | disclosed |
| US-10208051-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180162863-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2018-06-14 | — | — | US | disclosed |
| US-9896455-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-02-20 | — | — | US | disclosed |
| US-20160355520-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2016-12-08 | — | — | US | disclosed |
| US-8871776-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130102623-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2013-04-25 | — | — | US | disclosed |
| US-8314114-B2 | Tricyclic compounds having cytostatic and/or cytoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-08-25 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162863-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | TYMS 3/4885EGFR 334/4885PDGFRB 586/4885 |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | TYMS 3/4885EGFR 334/4885PDGFRB 586/4885 |
| US-20160355520-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DHFR, TK1, TYMS | TYMS 3/4885EGFR 334/4885PDGFRB 586/4885 |
| US-10208051-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DHFR, TK1, TYMS | TYMS 3/4885EGFR 334/4885PDGFRB 586/4885 |
| US-20130102623-A1 | Tricyclic Compounds Having Cytostatic and/or Cytotoxic Activity and Methods of Use Thereof | DHFR, TK1, TYMS | TYMS 3/4885EGFR 334/4885PDGFRB 586/4885 |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | TYMS 3/4885EGFR 334/4885PDGFRB 586/4885 |
| US-20110207757-A1 | Tricyclic Compounds Having Cytostatic and/or Cytoxic Activity and Methods of Use Thereof | DHFR, TK1, TK2 | TYMS 4/4885EGFR 327/4885PDGFRB 606/4885 |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DHFR, TK1, TYMS | TYMS 3/4885EGFR 334/4885PDGFRB 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.